632 related articles for article (PubMed ID: 8941409)
21. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Spriggs DR; Brady MF; Vaccarello L; Clarke-Pearson DL; Burger RA; Mannel R; Boggess JF; Lee RB; Hanly M
J Clin Oncol; 2007 Oct; 25(28):4466-71. PubMed ID: 17906207
[TBL] [Abstract][Full Text] [Related]
22. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
Meerpohl HG; du Bois A; Luck HJ; Kühnle H; Möbus V; Kreienberg R; Bauknecht T; Köchli O; Bochtler H; Diergarten K
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
Ozols RF
Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel plus carboplatin in the treatment of ovarian cancer.
Ozols RF
Semin Oncol; 1999 Feb; 26(1 Suppl 2):84-9. PubMed ID: 10190787
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer.
Fanning J; Colgrove M; Phibbs G
Gynecol Oncol; 2000 Oct; 79(1):97-100. PubMed ID: 11006039
[TBL] [Abstract][Full Text] [Related]
27. Carboplatin and paclitaxel in ovarian cancer.
Ozols RF
Semin Oncol; 1995 Jun; 22(3 Suppl 6):78-83. PubMed ID: 7541158
[TBL] [Abstract][Full Text] [Related]
28. Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer.
Markman M
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-24-S11-27. PubMed ID: 9314295
[TBL] [Abstract][Full Text] [Related]
29. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
30. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
31. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
32. Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma.
Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Renody N; Mularoni E; Soubrane C; Weil M; Mortier N; Khayat D
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-38-S2-40. PubMed ID: 9045335
[TBL] [Abstract][Full Text] [Related]
33. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
34. Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93).
Schink JC; Weller E; Harris LS; Cella D; Gerstner J; Falkson C; Wadler S
Cancer J; 2001; 7(2):155-64. PubMed ID: 11324769
[TBL] [Abstract][Full Text] [Related]
35. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy of advanced ovarian cancer: current status and future directions.
Ozols RF; Vermorken JB
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-1-S2-9. PubMed ID: 9045324
[TBL] [Abstract][Full Text] [Related]
37. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
Möbus V; Wandt H; Frickhofen N; Bengala C; Champion K; Kimmig R; Ostermann H; Hinke A; Ledermann JA; ;
J Clin Oncol; 2007 Sep; 25(27):4187-93. PubMed ID: 17698804
[TBL] [Abstract][Full Text] [Related]
38. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
Bunn PA; Kelly K
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy for advanced ovarian cancer: overview of randomized trials.
Thigpen JT
Semin Oncol; 2000 Jun; 27(3 Suppl 7):11-6. PubMed ID: 10952121
[TBL] [Abstract][Full Text] [Related]
40. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ;
J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
